News Article: Nutri Pharma's new soy composition found much more effective at reducing cholesterol than soy protein alone

soyatech.com, March 3 2003

Amersham, Bucks, February 2003 – A comparative study, emanating from a recent patent application, documents that Nutri Pharma’s soy composition Abacor®, is significantly more effective at lowering cholesterol compared to the best commercially available soy protein. The recent randomized, double-blind study was conducted in Berlin/Germany in cooperation with the German Institute for Food Research.

The study investigated the effects of the new patent pending composition of soy proteins and soy phospholipids, Abacor®, and the best commercially available soy protein on serum total, LDL and HDL cholesterol, triglycerides and apolipoprotein B. The trial proved Abacor® is significantly more effective in lowering serum lipids.

The positive results of the trial arise at an exciting time for Nutri Pharma. The Norwegian company has long been recognized as a leader in the R&D of soy technology. This position has been justified following the acceptance of a recent patent application, which has recently come into the public domain. The patent covers the use of a soy composition in the prevention and treatment of cardiovascular, and metabolic diseases amongst others. Abacor® is registered in all major international markets.

Nutri Pharma – founded by Dr Lars Hoie and Trond Syvertsen - in 1993, and with its science base going back to 1983 – has secured its intellectual property position with a very strong patent portfolio covering over 1000 patent claims for composition, process and methods of use. All patents are long lasting (until 2017-2024) and are approved or applied for in all major international markets.

Nutri Pharma's unique scientific and intellectual property places the company in a leadership position within the growing field of specialty soy ingredients. With its superior, well-documented and patented products and technologies, Nutri Pharma is positioned to provide product technologies to companies looking to take a lead in this market.

Nutri Pharma, mainly an R&D organization, is now seeking industrial partners in the food and pharma sectors with international reach for its patented technologies. For further information on Nutri Pharma and its patented soy technology please visit www.nutripharma.com or contact Mona Finston.
Phone 212-724-6117. Email mfinston@erols.com